Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Rhythm Pharmaceuticals Inc (RYTM) reported a solid quarter of BBS sales growth, indicating sustainable and steady growth in this area.
- The company had a successful Phase III readout of setmelanotide in acquired hypothalamic obesity, setting the stage for future growth.
- Rhythm Pharmaceuticals Inc (RYTM) is well-capitalized following an oversubscribed $189 million equity raise, strengthening its financial position.
- The company has expanded its market presence with IMCIVREE now available in over 20 countries outside the United States.
- Rhythm Pharmaceuticals Inc (RYTM) reported a 29% increase in global revenue quarter-over-quarter, driven by strong US and international sales.
- The company faces challenges in raising disease awareness and gaining access to approved medications in the ultra-rare disease community.
- There is uncertainty regarding the Prader-Willi study, which is characterized as exploratory with a 50-50 chance of success.
- Stock-based compensation expenses have increased significantly, impacting financial results.
- The company anticipates challenges in achieving off-label use of IMCIVREE in the US due to payer allegiance to the label.
- Named patient sales in international markets are variable and less predictable, affecting revenue consistency.
Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q2 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Dave Connolly, Investor Relations. Please go ahead.
Thank you, Tanya. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com. This morning, we issued our press release that provides our Q2 financial results and a business update, and that press release is available on our website. Our agenda is listed on slide 2.
On the call today are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, Chief Financial Officer; and Yann Mazabraud,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
